anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Thyroid endocrine disorders, including autoimmune thyroid disorders, occurred in 36.8% of LEMTRADA-treated patients in MS clinical studies (controlled and open-label extension). Newly diagnosed thyroid disorders occurred throughout the uncontrolled clinical study follow-up period, more than 7 years after the first LEMTRADA dose. Autoimmune thyroid disorders included Graves' disease, hyperthyroidism, hypothyroidism, autoimmune thyroiditis, and goiter. Graves' ophthalmopathy with decreased vision, eye pain, and exophthalmos occurred in 2% of LEMTRADA-treated patients. Seven patients required surgical orbital decompression. Serious thyroid events occurred in about 5.2% of LEMTRADA-treated patients in clinical studies and included cardiac and psychiatric events associated with thyroid disease. Of all LEMTRADA-treated patients, 3.8% underwent thyroidectomy.

Thyroid disease poses special risks in women who are pregnant [see Use in Specific Populations (8.1)].

Obtain thyroid function tests, such as TSH levels, prior to initiation of treatment and every 3 months thereafter until 48 months after the last infusion. Continue to test thyroid function after 48 months if clinically indicated or in case of pregnancy.

In patients with ongoing thyroid disorder, LEMTRADA should be administered only if the potential benefit justifies the potential risks.
FIELD: medicine. ^ SUBSTANCE: present invention concerns medical preparations, particularly a saturated powder to make a formulation with improved solubility and/or bioavailability of at least one active substance, containing a particle-like inert solid base, impregnated with a fluid medium containing hydrophobic and hydrophilic phases, at least one surface-active substance and at least one active substance. The powder is characterised that the active substance (the active substances) is (are) dissolved in one said hydrophilic or hydrophobic phases and in as a suspension in the other phases. Besides, the invention concerns the method for making and applying said powder. ^ EFFECT: claimed powder improves solubility and/or bioavailability of the active component. ^ 26 cl, 12 dwg, 6 tbl, 6 ex
A method for enhancing absorption and bioavailability of medically active or palliative ingredients comprising compounds or pharmaceutically acceptable salts thereof, the method comprising, in combination: ascertaining minimal dosage and required dissolution environments for selected medicaments; tabletting the medicament within sublingual delivery vehicles; and, creating the resultant products with enhanced bioavailability. The method applies primarily to controlled release sublingual formulations. Suitable active ingredients include pulmonary hypertension agents, vasodilators, cholesterol management tools, and agents for treating blood pressure. Several processes for producing sublingual dosage forms are outlined: in particular preparing sublingual compressed powder tablets of various shapes (e.g. round convex and round concave tablets to either slow dissolution or allow pooled saliva to improve dissolvability and reduce movement respectively), continuous eccentric sublingual capsule extrusion, offset gel strip extrusion, and sublingual waffle gel strip, dimpled gel strip and bubble gel strip preparation processes. The extruded forms preferably utilise gelatin.
An altered microbial exposure may be partly responsible for the increase of allergic diseases in populations with a western lifestyle. Activation of the immune system by microbes early in life is probably required for an accurate maturation of the immune system. Probiotics, live bacteria which are considered to confer health when ingested, have been suggested to prevent eczema and sensitisation infants.

The aim of this study is to assess the effect of oral supplementation with the probiotic bacterium Lactobacillus reuteri (L. reuteri) in infancy on the development of allergic disease and sensitisation during the first 2 years of life and to examine mechanisms possibly underlying eventual effects on allergic manifestations. In the study the development of allergic disease will also be related prospectively to immunological, nutritional and environmental factors.

The study is a prospective double-blind placebo-controlled multicenter trial, comprising 232 families with allergic disease. The families are recruited at the antenatal clinic, and the mothers will receive L. reuteri ATCC 55730 (1 x 100 000 000 colony forming units, Biogaia AB, Stockholm, Sweden) or placebo daily from gestational week 36 until delivery. Their babies then will continue with the same study product from birth until 12 months of age and will be followed up for another year. Clinical follow-up will be done at 1, 3, 6,12 and 24 months of age and telephone interviews at 2,4,5, 8, 10 and 18 months. A questionnaire will be completed on each occasion. Skin prick test will be performed at 6, 12 and 24 months of age. Venous blood will be collected from the umbilical cord and at 6, 12 and 24 months and stored as heparinized plasma or serum until assessment. Peripheral mononuclear blood cells (PBMC) will be separated from the plasma samples before storage. Blood samples will also be collected from the mother and father once during the study. The stool sample will be collected from the mother during the 1 week after delivery and the infant at 5-7 days, 1 month, 3 months, 6 months, 12 months and 24 months of age. Saliva samples will be collected at 3, 6, 12 and 24 months of age and breast milk samples will be collected from the mother 1-3 days and 1 months after delivery. The saliva, breast milk and plasma/serum samples will be stored in -20°C and stool samples and the PBMC in -70°C until assessment.

A follow up was performed at 7 years of age focusing on allergic disease. Spirometry, skin prick test was performed. Of the 188 completing the 2 year follow up, 184 also completed the 7 year follow up.
INTRODUCTION: The enlarged vestibular aqueduct (EVA) is the most frequent malformation of the inner ear associated with sensorineural hearing loss (5-15%). It exists when the diameter in imaging tests is greater than 1.5 mm at its midpoint. The association between hearing loss and EVA has been described in a syndromic and non-syndromic manner. It can appear as a familial or isolated form and the audiological profile is highly variable. The gene responsible for sensorineural hearing loss associated with EVA is located in the same region described for Pendred syndrome, where the SCL26A4 gene is located.
OBJECTIVE: To describe a series of children diagnosed with EVA in order to study their clinical and audiological characteristics, as well as the associated genetic and vestibular alterations.
METHOD: Retrospective study of data collection of children diagnosed with EVA, from April 2014 to February 2023.
RESULTS: Of the 17 cases, 12 were male and 5 were female. 5 of them were unilateral and 12 bilateral. In 5 cases, a cranial traumatism triggered the hearing loss. Genetic alterations were detected in 3 cases: 2 mutations in the SCL26A4 gene and 1 mutation in the MCT1 gene. 13 patients (76.5%) were rehabilitated with hearing aids and 9 of them required cochlear implantation.
DISCUSSION: The clinical importance of AVD lies in the fact that it is a frequent finding in the context of postneonatal hearing loss. It is convenient to have a high suspicion to diagnose it with imaging tests, to monitor its evolution, and to rehabilitate early.
Time-restricted eating is a novel nutrition intervention with evidence of beneficial effects on weight loss, blood glucose management, and other metabolic health outcomes. Adherence to time-restricted eating is higher than some traditional nutrition interventions to support individuals living with overweight/obesity and type 2 diabetes mellitus. However, there may be an evidence-practice gap of time-restricted eating in Australian dietetic practice. The present study aimed to explore dietitians' knowledge, experiences, and perspectives of time-restricted eating and timing of eating advice in practice. Semi-structured interviews with 10 private practice dietitians across Australia were conducted. Audio recordings were transcribed and analysed thematically. Six themes were identified: (i) distinction of time-restricted eating to other fasting protocols; (ii) knowledge of health benefits of time-restricted eating; (iii) patient-led advice frequently given: timing of breakfast and dinner; (iv) dietitian-led advice frequently given: eating cut-off time to avoid late night snacking; (v) barriers and facilitators to offering time-restricted eating or timing of eating advice; (vi) timing of eating advice within professional guidelines and resources. These findings suggest the need for development of professional resources and educational development tools for dietitians on time-restricted eating.
The placebo capsules contain no active ingredients. Subjects to take four (4) Placebo capsules by mouth daily for 180 days with a substantial meal.
PURPOSE:A hair treating agent, consisting of a combination of a solution of collagen in a dilute acid and a regenerating solution of collagen fibers, and capable of imparting a strong set holding power to hair without giving chemical changes to the hair. CONSTITUTION:A hair treating agent consisting of a solution of collagen in a dilute acid containing natural collagen extracted from animal tissues with a dilute aqueous solution of an acid (>=10<-3>M acid concentration) in an amount within 0.01-2wt% range as the first agent and a regenerating solution of collagen fibers, e.g. an aqueous solution of a water-soluble salt, pH buffer agent, e.g. partial sodium salt of citric acid, alkaline substance and protein precipitating agent, e.g. picric acid or chromic acid, as the second agent. The first and the second agents are mixed just before the treatment of the hair, and brought into contact with the washed hair in the same manner as a hair rinse agent and allowed to stand for several minutes to regenerate the collagen fibers. The hair is then lightly rinsed to remove excess water, set in a favorite hair style and dried in hot air. Thus, waves having improved water resistance, strong set holding power and good feeling are obtained.
The liver is one of the important organs that perform hundreds of essential functions in the body, it played a key role in lipid metabolism. However, the accumulation of lipid in the liver is limited because of its non-adipose tissue, so the excessive accumulation of lipids can lead to hepatocellular dysfunction or cell death, eventually leading to hepatic steatosis. Which may cause a variety of malfunction and inflammation symptoms such as nonalcoholic steatohepatitis, so by improving the abnormal metabolism of liver lipids, to prevent and reduce the risk of metabolic syndrome disease. Our invention has the best anti-oxidizing activity of the black garlic hot water extract in the simple and easy way, and the high-fat diet induced Syrian hamsters to induce liver lipid accumulation and to evaluate the supplemented with or without BG hot water extract whether the maintenance of liver function by liver biochemical activity tests. Results show that the liver glutathione (GSH) and antioxidant enzymes activity and lipid peroxidation level, results showed that high dose of BG hot water extract could increase the GSH and antioxidant enzymes activity in the liver GSH, catalase, glutathione reductase, glutathione peroxidase and Superoxide dismutase increased, moreover decreased lipid peroxidation index malondialdehyde content. Overall it was confirmed that feeding BG hot water extract could retard the oxidative damage caused by lipid accumulation and lipid peroxidation. In western blot assay HFD-induced hamsters liver the expression of and SCD-1, display BG hot water extract can slow down liver lipid synthesis and [beta]-oxidation. In conclusion, the hot water extracts of BG hot water extract have the highest antioxidant capacity and in animal experiments confirmed that the role of hamsters with ameliorates hyperlipidemia. BG hot water extract can be as a potential nutraceutical ingredient of hypolipidemic and hepatoprotection. The present invention is to reveal that the black garlic hot water extract has the effect of alleviates hepatic lipid accumulation injury.
In pyloric metaplasia, mature gastric chief cells reprogram via an evolutionarily conserved process termed paligenosis to re-enter the cell cycle and become spasmolytic polypeptide-expressing metaplasia (SPEM) cells. Here, we use single-cell RNA sequencing (scRNA-seq) following injury to the murine stomach to analyze mechanisms governing paligenosis at high resolution. Injury causes induced reactive oxygen species (ROS) with coordinated changes in mitochondrial activity and cellular metabolism, requiring the transcriptional mitochondrial regulator Ppargc1a (Pgc1α) and ROS regulator Nf2el2 (Nrf2). Loss of the ROS and mitochondrial control in Ppargc1a-/- mice causes the death of paligenotic cells through ferroptosis. Blocking the cystine transporter SLC7A11(xCT), which is critical in lipid radical detoxification through glutathione peroxidase 4 (GPX4), also increases ferroptosis. Finally, we show that PGC1α-mediated ROS and mitochondrial changes also underlie the paligenosis of pancreatic acinar cells. Altogether, the results detail how metabolic and mitochondrial changes are necessary for injury response, regeneration, and metaplasia in the stomach.
Method for obtaining a platelet-derived secretome and uses thereof. The present invention relates to a method for obtaining platelet secretomes and uses of the secretome in regenerative medicine (for therapeutic or aesthetic purposes), in the treatment of diseases, including cell therapy, and in vitro cell culture. This method is developed with the aim of obtaining platelet-derived bioproducts enriched in platelet granular load, rich in growth factors and depleted in other platelet-derived molecules and plasma for universal use (including donor-independence). and security). In addition, the potential processing of the product (nanoencapsulation, lyophilization) would allow additional clinical applications and solve storage limitations. This method and the characterization of secretomes at the molecular level in health and disease will contribute to the identification of biomarkers for the diagnosis and prognosis of diseases. Therefore, the present invention belongs to the fields of medicine, medical compositions, and disease diagnosis.  (Machine-translation by Google Translate, not legally binding)
Institute of Medicine (IOM) guidelines for weight gain in pregnancy are clear, but evidence-based treatment approaches are not widely available. This evidence gap is particularly pressing for medically vulnerable women - those who are low income and often racial/ethnic minorities. These women have the highest rates of obesity, but almost no resources to support weight control in pregnancy. Without intervention, most will exceed Institute of Medicine recommended gains and incur significant morbidity for themselves and their children. There is preliminary data from the investigators supporting the efficacy of digital health platforms for delivering antenatal obesity treatment among the medically vulnerable. However, the investigators' inexpensive, easily scalable approach has not been integrated and tested in real world settings, limiting broad reach and dissemination potential. Dissemination considerations are especially pressing for socioeconomically disadvantaged and minority populations because of these groups' higher obesity risk, greater potential for experiencing obesity-related comorbidities in pregnancy, and limited finances to afford alternative treatments. The Women, Infants and Children (WIC) Food and Nutrition Program is the leading public health nutrition program for pregnant women and their children in the US, and thus, it is in a unique position to meaningfully impact the obesity epidemic among the more than 9 million disadvantaged participants it serves annually. Yet no demonstrations of effective gestational weight gain interventions exist in WIC. The investigators propose a pragmatic trial designed to rigorously test their antenatal obesity treatment approach integrated into Philadelphia WIC community clinics. The investigators have long-standing relationships with WIC staff and prior experience conducting pragmatic clinical trials in under-resourced settings. The investigators will randomize 438 African American and Hispanic Philadelphia County WIC participants with obesity in early pregnancy to one of two treatment arms: 1) standard WIC care; or 2) an antenatal obesity treatment arm, which includes empirically supported behavior change goals, regular self-monitoring text messages with automated feedback, tailored skills training materials, and counseling from WIC nutritionists. The primary outcome is prevalence of excessive gestational weight gain; the investigators will additionally examine changes in diet and physical activity, health-related quality of life, and rates of adverse pregnancy outcomes. They will use the RE-AIM (Reach, Effectiveness, Adoption, Implementation, Maintenance) framework to evaluate the intervention's dissemination potential and cost effectiveness in the WIC setting. The proposed project will constitute the first systematic translation of a comprehensive antenatal obesity treatment program focused on low-income, racial/ethnic minorities, using the strengths of mHealth (mobile health) and WIC provider counseling for intervention delivery.
To date, there has been limited experience with overdosage of fluvastatin. If an overdose occurs, it should be treated symptomatically with laboratory monitoring and supportive measures should be instituted as required. The dialyzability of fluvastatin sodium and of its metabolites in humans is not known at present [see Warnings and Precautions (5)].

In the pediatric population, there have been reports of overdosage with fluvastatin sodium in children including a 2 year-old and the other 3 years of age, either of whom may have possibly ingested fluvastatin sodium. The maximum amount of fluvastatin sodium that could have been ingested was 80 mg (4 x 20 mg capsules). Vomiting was induced by ipecac in both children and no capsules were noted in their emesis. Neither child experienced any adverse symptoms and both recovered from the incident without problems. 

In the postmarketing experience there have been reports of accidental ingestion of fluvastatin tablets in infants up to 3 years of age. In one case, increased serum CPK values were noted. There have been reports of intentional overdose in adolescents with the development of hepatic enzyme elevations, convulsions and gastroenteritis/vomiting/diarrhea.
After consent, the endoscopist will perform a standard of care colonoscopy. If a polyp is found, then OCT will be used to image that polyp. Patients with polyps, regardless of number found, will have either one tubular adenoma (NICE type 2) imaged OR one hyperplastic polyp (NICE type 1) imaged. If no polyps are found, then one area of normal mucosa will be imaged. If on the rare chance a malignant appearing colonic tumor (NICE type 3) is found, this and no other polyps will be imaged with OCT.
BACKGROUND: To determine the association between optimality score at term age and age three to five months and neurodevelopmental outcome among neonates with hyperbilirubinemia.
METHODS: Fifty infants with and without hyperbilirubinemia were enrolled. The motor repertoires of the infants were evaluated through general movement assessment (GMA) at term age and three to five months post-term. The association between the General Movement Optimality Score (GMOS), Motor Optimality Score (MOS), and Development Assessment Scale for Indian Infants (DASII) at age 12 to 15 months was also assessed.
RESULTS: During term age, the median GMOS was significantly lower among infants in the study group when compared with the control group (40 [29 to 42] vs 42 [42 to 42], P < 0.001). However, at age three to five months, there was no significant difference between the groups. Significantly higher number of neonates had abnormal motor repertoire at term age and age three to five months in the study group when compared with the control group (18 [36%] vs 2 [4%], P = 0.001, at term age and 6 [12.2%] vs 1 [2%], P =0.04, at age three to five months). Among neonates with hyperbilirubinemia, the median GMOS and MOS were significantly lower at term age and age three to five months in infants with motor and mental developmental quotient scores <85 when compared with ≥85.
CONCLUSIONS: GMA including GMOS and MOS performed in neonates with hyperbilirubinemia during the neonatal period and early infancy is associated with neurodevelopmental outcomes in the first year of life. GMA can help initiate early intervention in such neonates.
BACKGROUND: Excessive smartphone usage among students can lead to discomfort in their hands and fingers. This study investigates the impact of smartphone holding posture, duration of usage, and the prevalence of wrist and finger pain among university students.
METHODS: This cross-sectional study involved 213 university students who were selected based on inclusion criteria. Data was collected through a demographic information questionnaire. Participants self-reported five different postures for holding and interacting with a smartphone. The prevalence, frequency, severity, and interference of wrist and finger discomfort were assessed using the Cornell Hand Discomfort Questionnaires (CHDQ).
RESULTS: The study revealed that the average age of participants was 21.3 ± 2.2 years. On average, they had been using smartphones for 7.9 ± 3.1 years and spent an average of 4.9 ± 2.5 h daily holding them in their hands. In terms of discomfort, more than 25% of students reported pain in areas C (thumb finger), E (Palm Pollicis), and F (wrist) of the right hand, which was significantly related to the duration of holding the smartphone in that hand. Additionally, smartphone holding duration significantly affected areas D (palm) and F of the left hand, with over 11% of students experiencing discomfort. The most prevalent posture among students (41% of participants) involved holding the smartphone with the right hand only, with the thumb touching the screen. Notably, areas B (χ2 = 21.7), C (χ2 = 10.27), D (χ2 = 65.54), and E (χ2 = 59.49) of the right hand, as well as areas C (χ2 = 6.58) and E (χ2 = 44.28) of the left hand, exhibited significant associations with the postures of holding the smartphone.
CONCLUSIONS: The duration of smartphone use and the postures in which it is held contribute to the prevalence of discomfort in the thumb area and related muscles among right-handed students.
The present invention relates to a medicine for treating bronchial asthma disease and a preparation method thereof. The medicine for treating bronchial asthma disease has a formula of medicine raw materials (part by weight): 6 to 100 of tag, 10 to 50 of small giant typhomium tuber, 4 to 30 of honey-fried herba ephedrae, 6 to 30 of dried old orange peel, 6 to 30 of pinellia tuber, 6 to 40 of tuckahoe, 2 to 15 of asarum, 4 to 30 of almond, 4 to 30 of fried tuckahoe and 2 to 15 of licorice root. The medicine of the present invention can mainly warm yang and build bodies, is used for thoroughly treating asthma, and solves the long standing problem of chronic inflammation in an air passage. The medicine can be used for superficially treating asthma by dispelling pathogenic wind and resolving convulsion, and solves the problems of the air passage hyperreactivity caused by the inflammation in an air passage and the caused smooth muscle convulsion. The formula of the present invention can effectively prevent and cure asthma by the synergistic action of the components. The medicine has the immune function of regulating an organism, and has the function of lightening the chronic inflammation in the air passage. The total effective rate is 98.8%, and the curative effect is obvious.